A severe clinical phenotype of Noonan syndrome with neonatal hypertrophic cardiomyopathy in the second case worldwide with RAF1 S259Y neomutation

Hager Jaouadi1, Amel Ben Chehida2,*, Lilia Kraoua3,*, Heather C. Etchevers4, Laurent Argiro4, Nadia Kasdallah5, Sonia Blibeche5, Valérie Delague6, Nicolas Lévy4, Néji Tebib2, Ridha Mrad3, Sonia Abdelhak1, Rym Benkhalifa6 and Stéphane Zaffran4

Abstract

Noonan syndrome and related disorders are a group of clinically and genetically heterogeneous conditions caused by mutations in genes of the RAS/MAPK pathway. Noonan syndrome causes multiple congenital anomalies, which are frequently accompanied by hypertrophic cardiomyopathy (HCM). We report here a Tunisian patient with a severe phenotype of Noonan syndrome including neonatal HCM, facial dysmorphism, severe failure to thrive, cutaneous abnormalities, pectus excavatum and severe stunted growth, who died in her eighth month of life. Using whole exome sequencing, we identified a de novo mutation in exon 7 of the RAF1 gene: c.776C > A (p.Ser259Tyr). This mutation affects a highly conserved serine residue, a main mediator of Raf-1 inhibition via phosphorylation. To our knowledge the c.776C > A mutation has been previously reported in only one case with prenatally diagnosed Noonan syndrome. Our study further supports the striking correlation of RAF1 mutations with HCM and highlights the clinical severity of Noonan syndrome associated with a RAF1 p.Ser259Tyr mutation.

1. Introduction

Noonan syndrome and related disorders (cardiofaciocutaneous syndrome [CFC], Costello syndrome [CS] and Noonan syndrome with multiple lentigines [formerly known as LEOPARD syndrome]) are autosomal dominant disorders characterized by a wide range of symptoms including facial dysmorphism, short stature, mental retardation and congenital heart defects often associated with hypertrophic cardiomyopathy (HCM) (Tartaglia et al., 2011). These syndromes, along with Legius syndrome and type I neurofibromatosis, are collectively known as RASopathies and share overlapping phenotypic and molecular features, making accurate diagnosis challenging (Nystrom et al., 2008; Tumurkhuu et al., 2010).

The molecular basis of these disorders has been linked to mutations in components or regulators of the Ras/mitogen-activated protein kinase (MAPK) pathway, predominantly encoded byPTPN11, BRAF, SOS1, Hras, KRAS, MAP2K1, MAP2K2 and RAF1 genes (Ko et al., 2008; Ezquieta et al., 2012; Search by Disease). The RAF1 gene encodes a proto-oncogene serine/threonine-protein kinase of 648 amino acids. Structurally, the Raf-1 (also known as c-Raf) protein has three conserved regions (CR). Mutations identified in this gene are clustered in the CR2 domain, with only a few located in CR3 (Pandit et al., 2007; Razzaque et al., 2008). The CR2 domain is important for the regulatory phosphorylation and binding with the 14-3-3 consensus site. Mutations located around Ser259 lead to decreased phosphorylation of the serine and dissociation from the 14-3-3 binding site, thus targeting the substrate to the catalytic domain in the CR3 domain (Kobayashi et al., 2010). Functional analysis showed that dephosphorylation of Ser259 by RAF1 mutations at this residue leads to extracellular signal-regulated kinases (ERK1 and ERK2) activation (Kobayashi et al., 2010).

HCM is frequently observed in patients with RASopathies and might represent the major determinant in the outcome of these patients (Limoncelli et al., 2006). Interestingly, a striking correlation between RAF1 mutations and HCM has already been described (Razzaque et al.,...
2007; Ko et al., 2008; Wilkinson et al., 2012; Gelb et al., 2015; Calcagni et al., 2018). It has been noted that Noonan syndrome patients with HCM have a worse risk profile compared to patients with idiopathic or familial HCM (Prendiville et al., 2014).

Here we report on a Tunisian patient with severe Noonan syndrome including neonatal HCM, leading ultimately to death. The aim of this study was to determine the genetic defect underlying the severe clinical phenotype of the patient.

2. Materials and methods

The parents provided their written informed consent to participate in this study. This work was conducted according to the principles of the Declaration of Helsinki and to the ethical guidelines of the institutions involved (Registration number: IRB00005445, FWA00010074). Genomic DNA was extracted from the samples according to standard techniques.

(i) Whole exome sequencing

Whole exome sequencing (WES) was performed for the parents, the affected child and her unaffected brother by the Genomics and Bioinformatics Platform (GBiM) of the INSERM U1251 Marseille Medical Genetics facility.

The samples were sequenced using library preparation protocols with the NimbleGen SeqCap EZ MedExome kit (Roche Sequencing Solutions, Madison, USA). The resulting libraries were subjected to paired-end sequencing on Illumina NextSeq 500 platform (Illumina, San Diego, CA, USA). Raw data were aligned against the human genome (hg19) using BWA 0.7.5. Variant calling and annotation were processed using GATK and ANNOVAR.

(ii) Variant prioritization

Pedigree-based variant prioritization and co-segregation were performed with the VariantAnnotation and Filtering Tool (VarAFT), version 2.12 (https://varaf.eu/). To pinpoint putatively pathogenic and causal variants we adopted the following filtering strategy: we first excluded variants with a minor allele frequency (MAF) >1% in the gnomAD database (http://gnomad.broadinstitute.org/). The remaining variants were filtered based on their type and genomic localization; thus, synonymous, intronic, variants in intergenic, 3´ and 5´ UTR regions were discarded. The obtained variants list was then filtered according to the in silico pathogenicity prediction. Thus, variants predicted as polymorphisms according to UMD-Predictor (http://umd-predictor.eu/), SIFT (http://sift.jcvi.org/), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), or Mutation Taster (http://www.mutationtaster.org/) were excluded. Subsequently, we searched for variants in the RAS/MAPK pathway by focusing on 20 genes previously associated with RASopathies (Table A1).

(iii) Sanger validation

The selected variant was validated using PCR-based bidirectional Sanger sequencing.

3. Results

(i) Clinical presentation

The patient, a Tunisian girl, was the second child of apparently healthy and unrelated parents. She had a healthy 4-year-old brother. The mother and the father were respectively 33 and 39 years at conception. The family history was unremarkable. Pregnancy was uneventful. The child was delivered by caesarian section in the 40th week of pregnancy because of engagement failure. The Apgar scores were 9 at one minute and 10 at 5 minutes. Her birth measurements were normal (50–90th percentiles) (Table 1).

She was admitted 42 hours after birth in the neonatal department because of dyspnea, cardiac murmur and dysmorphic facial features. At 5 days, she was diagnosed with non-obstructive hypertrophic cardiomyopathy with a moderate pulmonary hypertension at 46 mmHg. She was treated with propranolol (4 mg/day). Transfontanellar and renal ultrasound examination were normal. Serum creatinine, thyroid function tests, ammonia and lactate levels were normal. Complete blood count revealed hypochromic anemia treated with iron therapy. The mother’s HbA1c was normal (5.1%), R-banded chromosome analysis on cultured peripheral blood lymphocytes from the patient was normal 46,XX. The chest computed tomography scan, carried out at 12 days, ruled out coarctation of the aorta. Rhythm Holter, carried out at 40 days, showed a normal sinus rhythm with heart rate of 133 beats per minute and increased P wave amplitude. Echocardiography controlled at 5 months showed concentric asymmetric hypertrophy of the ventricles and interventricular septum leading to a mild right ventricular outflow tract obstruction (maximum gradient between pulmonary artery and right ventricle = 16 mm) (Figure 1 & Table 1). A patent foramen ovale and a moderate dynamic mitral insufficiency were also noted.

Consequently, the girl was referred to a pediatric and metabolic department for further investigations. Clinical evaluation by pediatricians and geneticists found a severe failure to thrive (Table 1). The dysmorphic facial features including large forehead, frontal bossing, bitemporal narrowing, shallow orbital ridge, hypertelorism, epiphosphalos, down-slaning palpebral fissures, depressed root of nose and moderate bulbous tip, anteverted nares, low-set, posteriorly rotated ears with thickened helix, smooth long philtrum, small mouth, thin lips, retrognathia and a short neck with excess nuchal skin (Figure 2). Cutaneous abnormalities were remarkable including sparse hair, eyebrows and eyelashes, redundant and loose skin on body members, hands and feet, and deep palmoplantar creases (Figure 2). A pectus excavatum and umbilical hernia were also noted. Heart auscultation indicated systolic murmur without features of heart failure. Neurologic examination showed axial and peripheral hypertonia with large joint stiffness. Metabolic investigations (lactate cycle, plasma free and total carnitine levels, chromatographic analysis of amino acids and organic acids) were normal. The patient was diagnosed with Noonan syndrome or CFC, as key features of these syndromes were present, namely the characteristic facies, the failure to thrive, the HCM, the pectus excavatum and the cutaneous abnormalities. Molecular testing for a germline RASopathy was indicated.

At the age of 6 months, at blood sampling, the patient showed some changes in facial appearance; the philtrum became deeply grooved, the lips thicker, the nose bulbous and the cheeks full, which were most suggestive of Noonan syndrome (Figure 2).

On the last evaluation, at 8 months, she had a severe stunted growth (Table 1), more evident dysmorphic face, cardiac murmur, mild hepatomegaly, normal psychomotor development and a normal pulmonary examination. However, she died at home of a respiratory infection a few days later.
Table 1. Evolution of growth and echocardiographic features.

<table>
<thead>
<tr>
<th>Age</th>
<th>Neonatal (first week)</th>
<th>5 months</th>
<th>8 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight</td>
<td>Grams</td>
<td>3600</td>
<td>4300</td>
</tr>
<tr>
<td>Percentile</td>
<td>50–75th</td>
<td>&lt;3rd</td>
<td>&lt;3rd</td>
</tr>
<tr>
<td>Height</td>
<td>Centimeters</td>
<td>49.5</td>
<td>54</td>
</tr>
<tr>
<td>Percentile</td>
<td>50th</td>
<td>&lt;3rd</td>
<td>&lt;3rd</td>
</tr>
<tr>
<td>Head circumference</td>
<td>Centimeters</td>
<td>37</td>
<td>40</td>
</tr>
<tr>
<td>Percentile</td>
<td>90th</td>
<td>&lt;3rd</td>
<td>&lt;3rd</td>
</tr>
<tr>
<td>IVS</td>
<td>mm</td>
<td>9</td>
<td>10</td>
</tr>
<tr>
<td>PLVW</td>
<td>mm</td>
<td>6</td>
<td>8</td>
</tr>
</tbody>
</table>

IVS, interventricular septum thickness; NA, not available; PLVW, posterior left ventricular thickness.

Fig. 1. Echocardiogram at the age of 5 months showing concentric HCM (a) and right ventricular outflow tract dilation (b).

Fig. 2. Photographs of the patient at 5 months (a, b, e, f, g) and 6 months (c, d): note the dysmorphic facial features (a, b, c, d) including large forehead, frontal bossing, bitemporal narrowing, shallow orbital ridge, hypertelorism, exophthalmos, down-slanting palpebral fissures, depressed root of nose and bulbous tip, anteverted nares, low-set, posteriorly rotated ears with thickened helix (b, d), smooth long philtrum (a) becoming deeply grooved (c), small mouth, thickening of lips (c), full cheeks (c) and retrognathia (b, d) and the cutaneous abnormalities including sparse hair, eyebrows and eyelashes (a, b, c, d), redundant and loose skin on body members (e), hands and feet (f), and deep palmoplantar creases (g).
To review the mutation spectrum of Noonan syndrome and specifically the \textit{RAF1} gene, the European Network on Noonan Syndrome and related disorders was queried. The \textit{PTPN11} gene is the most implicated gene in Noonan syndrome (61%), followed by \textit{SOS1} and \textit{RAF1} genes (15 and 6%, respectively). Approximately 91% of \textit{RAF1} variants are associated with Noonan syndrome (Search by Disease). Moreover, six variant alleles were reported at the Ser259 residue (Table 2). The p.Ser259Tyr has only been reported once in a fatal case of Noonan syndrome (Hakami et al., 2016).

To assess the functional impact of the p.Ser259Tyr variant, several \textit{in silico} prediction tools were used (Table 3).

Moreover, the \textit{RAF1} c.776C>G; p.Ser259Tyr variant identified by WES confirms the diagnosis of Noonan syndrome in our patient.

(ii) Whole exome sequencing

Considering the overlapping features between Noonan and CFC syndrome in our patient, her severe clinical profile and the genetic heterogeneity of RASopathies, we performed exome sequencing of the patient, her unaffected brother and both parents to identify the disease-causing mutation. WES data from the family were simultaneously analysed and segregated using VarAFT to identify the disease-causing mutation. WES data from the family were simultaneously analysed and segregated using VarAFT to identify the disease-causing mutation. The patient had remarkable dermatological features including sparse hair, eyebrows and eyelashes, redundant skin and deep palmar/plantar creases. Of note, sparse hair, sparse eyelashes and cutaneous abnormalities can be pronounced in CFC syndrome (Lee et al., 2011).

WES was performed and showed a de novo p.Ser259Tyr mutation in exon 7 of \textit{RAF1}. \textit{RAF1} or CRAF is an entry point to the MAPK pathway. It acts as a downstream effector of RAS signalling alongside BRAF (Dhillon et al., 2002). \textit{RAF1} activation initiates a MAPK cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases MEK1/MEK2 (encoded by the \textit{MAP2K1} and \textit{MAP2K2} genes) followed by the extracellular signal-regulated kinases ERK1 and ERK2 (encoded by \textit{MAPK3} and \textit{MAPK1}, respectively) (Dhillon et al., 2002; Pandit et al., 2007). The conserved region CR2 of \textit{RAF1} plays a key role in its activation. Interestingly, the majority of \textit{RAF1} mutations are located in the CR2 domain. Functional characterization showed that the \textit{in vitro} activity of \textit{RAF1} proteins with mutations in the CR2 domain are higher than the activity of normal \textit{RAF1} in the presence of growth factor (Lee et al., 2011).

4. Discussion

We report on an 8-month-old girl affected with Noonan syndrome and neonatal HCM. She had a severe clinical phenotype, resulting in a fatal outcome. The clinical presentation included neonatal HCM, facial dysmorphism, severe failure to thrive, cutaneous abnormalities and pectus excavatum. These clinical and dysmorphic facial features were suggestive of Noonan syndrome. Nevertheless, the patient had remarkable dermatological features including sparse hair, eyebrows and eyelashes, redundant skin and deep palmar/plantar creases. Of note, sparse hair, sparse eyelashes and cutaneous abnormalities can be pronounced in CFC syndrome (Lee et al., 2011).

WES was performed and showed a de novo p.Ser259Tyr mutation in exon 7 of \textit{RAF1}. \textit{RAF1} or CRAF is an entry point to the MAPK pathway. It acts as a downstream effector of RAS signalling alongside BRAF (Dhillon et al., 2002). \textit{RAF1} activation initiates a MAPK cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases MEK1/MEK2 (encoded by the \textit{MAP2K1} and \textit{MAP2K2} genes) followed by the extracellular signal-regulated kinases ERK1 and ERK2 (encoded by \textit{MAPK3} and \textit{MAPK1}, respectively) (Dhillon et al., 2002; Pandit et al., 2007). The conserved region CR2 of \textit{RAF1} plays a key role in its activation. Interestingly, the majority of \textit{RAF1} mutations are located in the CR2 domain. Functional characterization showed that the \textit{in vitro} activity of \textit{RAF1} proteins with mutations in the CR2 domain are higher than the activity of normal \textit{RAF1} in the presence of growth factor (Lee et al., 2011).
mutants in the CR2 domain impaired phosphorylation of Ser259, abrogated the binding to the 14-3-3 site and lead to a partial activation of ERK (Kobayashi et al., 2010; Tumurkhuu et al., 2010). Thus, the lack of phosphorylation of Ser259 is the primary pathogenic mechanism in activating RAF1 mutants (Dhillon et al., 2002; Kobayashi et al., 2010). Gain-of-function mutations in the RAF1 gene lead to constitutive activation of the RAS/MAPK pathway (Hopper et al., 2015).

Gain-of-function mutations in RAF1 were identified in 3–17% of patients with Noonan syndrome and two patients with Noonan syndrome with multiple lentigines (Pandit et al., 2007; Razzaque et al., 2007). In a case series study reporting 212 newborns with clinical suspicion of Noonan syndrome and related disorders, the RAF1; p.Ser259Tyr mutation was reported in one patient with Noonan syndrome (Hakami et al., 2016). No clinical data of this patient were provided, except a severe edema detected by ultrasonography (Hakami et al., 2016). Therefore, our patient is the second case reported in the literature carrying the p.Ser259Tyr mutation. However, allelic heterogeneity at Ser259 residue was noted (Table 2). As an illustration, the p.Ser259Thr mutation was functionally characterized by assaying the activation status of the downstream effectors, MEK2 and ERK2. In the presence of epidermal growth factor stimulus, a higher level of phosphorylated MEK1 and ERK2 was observed in cells expressing p.Ser259Thr than in those expressing wild-type RAF1 (Lee et al., 2011).

Our patient had neonatal non-obstructive HCM with mild pulmonary hypertension. Previous studies noted that HCM in Noonan syndrome arises early in life, with a median age of 5 months (Hickey et al., 2011; Wilkinson et al., 2012). HCM might represent the major determinant in the outcome of these patients (Limonelli et al., 2006; Wilkinson et al., 2012), particularly in patients with early onset of HCM (Calcagni et al., 2018). HCM and pulmonic stenosis are the most common cardiac abnormalities in RAF1 mutation carriers (Kobayashi et al., 2010). Sudden deaths in patients with RAF1 mutations has been likely associated with heart abnormalities and their complications (Kobayashi et al., 2010; Wilkinson et al., 2012). The molecular pathogenesis of HCM in RASopathies results from hyperactivation of several signalling pathways (Calcagni et al., 2018). Pandit et al. noted that Noonan syndrome patients with HCM carried gain-of-function RAF1 mutations resulting in increased ERK activation, whereas Noonan syndrome patients without HCM harbour loss-of-function RAF1 mutations (Pandit et al., 2007). These findings suggest that enhanced ERK activation may underlie cardiomyocyte hypertrophy.

Interaction of signal transduction pathways such as the MAPK pathway and their activators may underlie cardiac hypertrophy (Rohini et al., 2010). The exposure of cardiomyocytes to stress leads to the activation of small G proteins such as Ras and Raf, which further activates MAPK signalling. Hence, the activation of the RAS/RAF/MEK/MAPK cascade is an integral part of the pathogenesis of HCM (Sala et al., 2012). Of note, in vivo inhibition of MEK attenuates cardiac growth in both induced and genetic models of hypertrophy (Armstrong, 2004; Sala et al., 2012).

Fig. 3. Pedigree of the family. Affected proband is denoted by filled circle, unaffected members are denoted by empty symbols. Sequence electropherograms are shown below symbols. (+) indicates the wild-type allele, the arrow indicates the position of the mutation.
At 5 months, echocardiography of our patient revealed a concentric asymmetric hypertrophy of the ventricles and interventricular septum. Indeed, biventricular hypertrophy has been noted in patients with Noonan syndrome carrying RAF1 mutations (Sana et al., 2014; Thompson et al., 2017). Moreover, HCM in RASopathies is characterized by asymmetrical hypertrophy with major involvement of basal interventricular septum (Calcagni et al., 2018). Altogether, the clinical presentation described in this study and the in silico prediction of the functional impact of RAF1 p.Ser259Tyr mutation strengthens its claim to pathogenicity.

In conclusion, WES allowed us to identify a de novo p.Ser259Tyr mutation in RAF1 and to provide a definite diagnosis of Noonan syndrome. Differential diagnosis of Noonan syndrome and related disorders is relevant due to their different management and prognosis as well as the resulting genetic counselling. In the present family, as the p.Ser259Tyr mutation occurred de novo, the clinical impact for future pregnancies is low (<1%). Moreover, no medical follow-up will be required for their healthy second son. This report further supports the implication of RAF1 gene analysis, and genotype–phenotype correlation in Korean patients with Noonan syndrome. Journal of Human Genetics 53(11–12), 999–1006.


References

